Dr. Ganapathi Bhat M.
Verified Senior ConsultantOncologyJaslok Hospital

Dr. Ganapathi Bhat M.

Qualifications:MBBS, DNB
Experience
28+ Years
Surgeries
1000+ Done
Primary Hospital
Jaslok Hospital
Second Opinion
24–48h

Professional Background & Biography

Dr. Ganapathi Bhat M. is an eminent personality, presently appointed as a Sr. Consultant in the Department of Medical Oncology and Stem Cell Transplant since 2006 at Jaslok Hospital and Research Centre, Mumbai. His major area of responsibility is Hematopoietic Stem Cell Transplantation where as a core team member of Transplant Unit he has successfully performed more than 400 cases of both Autologous and Allogenic (including MUD &haploidentical) Transplants. Dr. Bhat takes pride in conducting the "World's First Case" of post renal transplant plasmacytoma. He Has also carried out successfully the first case of NHL in a seropositive patient in India. He has vast experience of two decades of treating various solid tumors and hematological malignancies with chemotherapy, targeted therapy, and immunotherapy. He is also part of PRRT therapy in treatment of Metastatic neuroendocrine tumor and hormone resistant prostate cancer. Dr. Bhat is actively involved in various teaching and academic programmes as a renowned faculty for DNB Oncology (super-specialty) and DNB Medical at Mumbai. Currently, he is mentor for MSc and PhD students in applied biology and fellowship in Medical Oncology (under MUHS) for Mumbai University.

Clinical Focus & Areas of Expertise

Targeted & Immunotherapy
CAR-T Cell Therapy
Radioimmunotherapy In Lymphoma
Radiopeptide Therapy
Clinical Application Of Mesenchymal Stem Cells In Regenerative Medicine

Key Procedures & Surgical Treatments

Chemotherapy
Acute Lymphocytic Leukemia - ALL in Adults
Stem Cell Transplant
Targeted Therapy
Zevalin therapy in NHL
Radio-peptide in NET & Metastatic Carcinoma of Prostate therapy
Cell therapy in autoimmune disorders
Radiation oncologists Haematologists Immunotherapy Cellular therapy

Positions & Hospital Appointments

Consultant, Kuwait Cancer Control Centre
Consultant, Lilavati Hospital and Research Centre Mumbai

Professional Memberships & Affiliations

Member of Asian Pacific Bone Marrow Transplantation-since 2014
Member of European Hematology Association: Admitted as Member Of European hematology Association in April 2005. (Membership No-4010)
Member of European Society of Medical Oncology: Admitted as Member of European Society of Medical Oncology in June 2005.
Member of American Association for Cancer Research: Admitted as an Affiliate
Member in good standing of American Association for Cancer Research in July 2005.(Membership No-123632)
Member of the college of Chest Physicians of India : Admitted as Member of the college of Chest Physicians of India, in Feb.1996 "

Select Clinical Research & Publications

Incidence and prognostic significance of anemia in non-Hodgkin’s lymphoma patients. ABSTRACT SECTION [72-81, iii57]- ESMO SUMMER EDUCATIONAL CONFERENCE, EDINBURG,SCOTLAND,UK,JUNE 2003. Kamlesh.p.sajnaniGanapathi.bhat.Salem Shemmari
Evaluation of cyclic chemotherapy in non Hodgkin’s lymphoma patients infected with chronic hepatitis. POSTER SESSION [ABSRACT BOOK-1016] ECCO-12 COPENHAGEN. SEPT 2003 .K.Kamlesh P Sajnani, G.Ganapathi Bhat,I.Iqbal Siddique,S.Al- Shemmari,F.Fuad Al-Ali Citation-European Cancer Conference Abstract book,Vol I No Sept 2003,1016.
Primary extra nodal lymphomas: analyses of clinical characteristics a single centre experience. POSTER SESSION [ABSTRACT BOOK 599P], ESMO 29 TH CONGRESS VIENNA. OCT –NOV 2004(Annals of Oncology supplement 3,vol 15,2004,abstract book 29 th ESMO Congress) Ganapathi.M.Bhat,Salem Al-Shemmari,Reem Ameen,Kamlesh P Sajnani,Jan Gyarfas.
Non-Hodgkin’s lymphoma in elderly patients- a retrospective single institution analysis. POSTER SESSION.GERIATRIC ONCOLOGY CONFERENCE (SOUVENIR &ABSTRACT BOOK). OCTOBER 14-16,2005.Tata Memorial Hospital.Mumbai.India. Ganapahi.Bhat.M.,Salem Al-Shemmari.,Kamlesh P.Sajnani.,Jan Gyarfas.
Analysis of Clinical Characteristics and Prognostic variables of Hodgkin’s Lymphoma: A single Center Experience.Absract section,Publication Number 4647.47th ASH Annual Meeting Dec.2005,New Orleans,LA.(Citation –Blood,DEC.2005.November abstract issue). Salem Al-Shemmari., Ganapahi.Bhat.M., Kamlesh P.Sajnani.,Reem Ameen.
Clinical profile and acute adverse events in Stem Cell Transplantation: - Jaslok Hospital Experience.Poster presentation,Ganapathi.Bhat.M., Suvarna .Achrekar.,Anjana Sainani., Reetu Jain.,Chetna Bakshi., Akshay Shah., Sujata Vasani.Mehboob Basade.,Samir.S.Shah.,Boman N.Dhabhar Tapan K.Saikia., S. H .Advani.Division of Medical Oncology and Bone marrow transplant Unit Jaslok Hospital and Research Centre , Mumbai; Mumbai Hematology Group Annual Conference 14-15th April 2007,Tata Memorial Hospital, Mumbai
Impact of CD34+cells as predictor of Hematopoietic recovery in Autologous Peripheral Blood Stem Transplant-Single center experience.Oral presentation, Suvarna.Achrekar.Ganapathi.Bhat.M., Mamta Yargop,Anjana Sainani.,VPAntia,Reetu Jain.,Chetna Bakshi.,Akshay Shah.,Sujata Vasani., Tapan K.Saikia.,S. H .Advani.Division of Medical Oncology and Bone marrow transplant Unit Jaslok Hospital and Research Centre , Mumbai; Mumbai Hematology Group Annual Conference 14-15th April 2007,Tata Memorial Hospital, Mumbai
Stem cell transplant in diabetes –a long road ahead- 04/12/2012, 5 th Bits WORLD conference of Regenerative Medicine and Stem Cell Research-2012, Guanzchou, China.
Probing Mesenchymal stem cells from lab to life: Are we poised to signal the dawn of a new frontier? DR.GANAPATHI.BHAT.M. abstract selected for oral presentation- 3 rd world congress of stem cell research and cell science 2013, Baltimore, USA. Nov.20-23,2013.
Probing mesenchymal stem cells from lab to life: Are we poised to signal the dawn of a new frontier? DR.GANAPATHI.BHAT.M. abstract selected for oral presentation- 3 rd world congress of stem cell research and cell science 2013, Baltimore, USA. Nov.20-23,2013
Direct Case Review

Consult Dr. Ganapathi Bhat M.

Send your reports for a free physician evaluation, treatment plan, and hospital package roadmap.

Confidential review under HIPAA protocols
Specialist response within 24–48 hours